Rapid sepsis test SeptiLoop

bacterialateral flow

We have developed a new first-class in vitro cellular immunoassay that detects sepsis within the first hour of bloodstream infection. Our patented method and kit identify immune activity biomarkers with a sensitivity 3 times greater than the leading competito. Additionally, our diagnostic process is 10 times faster than pathogen identification. Our biomarker can be detected as early as one hour after infection, significantly earlier than the current standard biomarker (PCT). This early detection will enable healthcare providers to initiate accurate treatment at an earlier stage, reducing disease severity and minimizing the need for antibiotics or other drugs. Line of R&D project in SMEs 04/18/SO/0017 funded by Unlike traditional methods that focus on pathogen identification, our approach measures the status and response of the immune system of the septic patient. SeptiLoop can diagnose bacteremia as early as one hour after infection and throughout all stages of sepsis, enabling healthcare professionals an early detection and timely treatment initiation. SeptiLoop offers compelling advantages: Early Detection SeptiLoop’s novel approach based on immune activity allows for the detection of sepsis within the first hour of infection. Enhanced Accuracy SeptiLoop exhibits a remarkable 3x increase in accuracy compared to current tests Cost-effective and User-friendly SeptiLoop is designed as a point-of-care device, eliminating the need for extensive laboratory infrastructure. Rapid Results